Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:APGENYSE:DNANASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$69.21+0.0%$63.07$52.50▼$70.48$1.51B0.49270,846 shs299,660 shsAPGEApogee Therapeutics$33.11+3.3%$35.20$26.20▼$63.50$1.49B1.72506,799 shs347,971 shsDNAGinkgo Bioworks$7.84-3.2%$8.44$5.00▼$45.20$454.70M1.341.50 million shs1.14 million shsJANXJanux Therapeutics$29.69+3.5%$30.80$22.52▼$71.71$1.75B3.27852,291 shs367,166 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.01%+6.28%+7.77%+18.39%+5.70%APGEApogee Therapeutics+3.34%+10.59%-14.73%-10.66%-35.71%DNAGinkgo Bioworks-3.27%+7.11%+7.70%-27.55%-83.11%JANXJanux Therapeutics+3.49%+10.49%-4.01%-27.09%-38.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.6208 of 5 stars2.51.00.03.33.33.31.3APGEApogee Therapeutics2.1058 of 5 stars3.50.00.00.02.74.20.0DNAGinkgo Bioworks0.6215 of 5 stars0.81.00.00.01.92.51.3JANXJanux Therapeutics2.7051 of 5 stars3.51.00.00.03.05.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$79.7515.23% UpsideAPGEApogee Therapeutics 3.00Buy$92.17178.37% UpsideDNAGinkgo Bioworks 1.60Reduce$4.58-41.61% DownsideJANXJanux Therapeutics 3.09Buy$95.25220.82% UpsideCurrent Analyst Ratings BreakdownLatest DNA, ANIP, JANX, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.003/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.003/14/2025ANIPANI PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.003/13/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$95.003/12/2025ANIPANI PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.003/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.003/5/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$84.00 ➝ $86.003/3/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.003/3/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.003/3/2025JANXJanux TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.002/28/2025JANXJanux TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$62.00 ➝ $41.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.45$7.66 per share9.03$21.13 per share3.28APGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/ADNAGinkgo Bioworks$227.04M2.00N/AN/A$21.93 per share0.36JANXJanux Therapeutics$10.59M165.74N/AN/A$7.46 per share3.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$18.78M-$1.14N/A16.44N/A-1.28%15.87%6.88%5/9/2025 (Estimated)APGEApogee Therapeutics-$83.99M-$3.29N/AN/AN/AN/A-21.81%-20.94%5/12/2025 (Estimated)DNAGinkgo Bioworks-$892.87M-$10.68N/AN/AN/A-298.78%-58.54%-34.24%5/8/2025 (Estimated)JANXJanux Therapeutics-$58.29M-$1.28N/AN/AN/A-463.91%-10.47%-9.86%5/6/2025 (Estimated)Latest DNA, ANIP, JANX, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19N/AN/AN/AN/AN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37N/AN/AN/A$179.75 millionN/A5/8/2025Q1 2025DNAGinkgo Bioworks-$1.23N/AN/AN/AN/AN/A5/6/2025Q1 2025JANXJanux Therapeutics-$0.42N/AN/AN/A$0.59 millionN/A3/3/2025Q4 2024APGEApogee Therapeutics-$0.94-$1.19-$0.25-$1.19N/AN/A2/27/2025Q4 2024JANXJanux Therapeutics-$0.49-$0.36+$0.13-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.522.741.97APGEApogee TherapeuticsN/A16.3916.39DNAGinkgo BioworksN/A5.795.79JANXJanux TherapeuticsN/A38.8038.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%APGEApogee Therapeutics79.04%DNAGinkgo Bioworks78.63%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%APGEApogee Therapeutics36.10%DNAGinkgo Bioworks9.72%JANXJanux Therapeutics29.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.77 million18.36 millionOptionableAPGEApogee Therapeutics9145.03 million28.77 millionOptionableDNAGinkgo Bioworks64058.03 million51.89 millionOptionableJANXJanux Therapeutics3059.11 million37.05 millionOptionableDNA, ANIP, JANX, and APGE HeadlinesRecent News About These CompaniesGeode Capital Management LLC Boosts Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)April 17 at 3:23 AM | marketbeat.comJPMorgan Chase & Co. Boosts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)April 16 at 3:20 AM | marketbeat.comQuinn Opportunity Partners LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)April 14, 2025 | marketbeat.comFmr LLC Acquires 845,266 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)April 12, 2025 | marketbeat.com9,378 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Sei Investments Co.April 12, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Reaches New 1-Year Low - Time to Sell?April 11, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Vanguard Group Inc.April 10, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires 18,509 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)April 9, 2025 | marketbeat.comWellington Management Group LLP Acquires 520,898 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)April 9, 2025 | marketbeat.comSpringhill Fund Asset Management HK Co Ltd Invests $1.59 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)April 8, 2025 | marketbeat.comTrexquant Investment LP Buys New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX)April 8, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Franklin Resources Inc.April 8, 2025 | marketbeat.comJanux Therapeutics: What's My Inflection Point?April 7, 2025 | seekingalpha.comJanux Therapeutics: What's My Inflection Point?April 7, 2025 | seekingalpha.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Rhenman & Partners Asset Management ABApril 7, 2025 | marketbeat.comPamalican Asset Management Ltd Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)April 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Schroder Investment Management GroupApril 6, 2025 | marketbeat.comJanux Therapeutics: Buying For The Promising Pipeline, Holding For The BuyoutApril 5, 2025 | seekingalpha.comJanux Therapeutics (NASDAQ:JANX) Trading Up 7.5% - Still a Buy?April 4, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Reaches New 12-Month Low - Should You Sell?April 4, 2025 | marketbeat.comPictet Asset Management Holding SA Purchases New Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)April 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNA, ANIP, JANX, and APGE Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$69.21 +0.01 (+0.01%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$69.22 +0.01 (+0.01%) As of 04/17/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Apogee Therapeutics NASDAQ:APGE$33.11 +1.07 (+3.34%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$33.16 +0.05 (+0.14%) As of 04/17/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Ginkgo Bioworks NYSE:DNA$7.84 -0.26 (-3.15%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$7.88 +0.04 (+0.51%) As of 04/17/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Janux Therapeutics NASDAQ:JANX$29.69 +1.00 (+3.49%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$29.66 -0.03 (-0.08%) As of 04/17/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Tariff-Resistant Abbott Laboratories on Track for New Highs Goldman Sachs Just Revealed What’s Next for Markets United Airlines Is in Reversal—If the Economy Doesn’t Stall Buy the Boeing Dip Even on Tariff and Bans? Spotify Stock Climbs as Its Growth Strategy Diversifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
